Hancom Healthcare announced on the 24th that it will jointly develop and supply a Corona 19 neutralizing antibody diagnostic kit in cooperation with HB Healthcare, a diagnostic specialist.
As a result, Hancom Healthcare expanded its lineup of quarantine products by entering the diagnostic kit business following the quarantine mask.
Hancom Healthcare established a company-affiliated bio research institute and is actively promoting the development of quarantine products in the bio field. HB Healthcare is a new bio-venture company established earlier this year by experts in the field of diagnostic kits, including CEO Kim Gyeong-tak.
Recently, as the case of emergency use approval (EUA) for a neutralizing antibody diagnostic kit emerged for the first time in the United States, interest in the neutralizing antibody diagnostic kit is increasing in Korea. A neutralizing antibody is one of the binding antibodies produced when a virus invades in the body, and is a major antibody that prevents reinfection and neutralizes the virus by preventing the virus from penetrating into cells. In the industry, it is regarded as a key indicator of immunity against the Corona 19 virus.
Although commercially available diagnostic kits can only check the presence or absence of antibodies or infection history, the neutralizing antibody diagnostic kit requires relatively higher technology because it can confirm whether immunity has been formed through quantitative analysis of neutralizing antibodies among antibodies.
The product jointly developed by the two companies is the neutralizing antibody diagnostic kit’HBelisaTM SARS-CoV-2 Neutralizing Antibody Detection Kit’. The antigenic protein used here was developed with our own technology. It is based on the ELISA (enzyme immunity method), which diagnoses blood directly from the kit.
The existing neutralizing antibody standard test method, PRNT (Plaque Inhibition Test), requires a demanding level of laboratories and experts and takes 3 to 5 days for diagnosis, whereas HBELLY can diagnose only with a small amount of blood, and the diagnosis time is also required. The accuracy of the results is the same, while significantly shortening it within 90 minutes. In addition, it has the advantage of being able to measure 90 samples at the same time, and to quantify and analyze viruses by ratio and numerical value.
The two companies will start supplying HVellisa as research products to vaccine developers, vaccine research institutes, and research institutes, and plan to expand domestic supply to hospitals, clinical sites, and vaccinationists through an approval process in the future. It plans to export to Europe.
Related Articles
Hancom joins’KT Cloud One Team’… Target of expanding native cloud ecosystem
Hancom Robotics, Seoul National University and AI Guide Robot Big Data Construction
Hangul and Computer to unveil’Hancom Works’, an AWS-based collaboration platform
Hancom Intelligence, Online’Altium Road Show’ held on the 26th
HB Healthcare CEO Kim Gyeong-tak said, “We have secured an edge in the diagnostic kit market with excellent performance and economical efficiency through our own production of raw materials and securing our own technology compared to domestic and foreign competitors that license core technologies and raw materials.”
Oh Byung-jin, CEO of Hancom Healthcare, said, “Starting with this neutralizing antibody diagnostic kit, we plan to secure a diagnostic product line ranging from molecules, antigens, and antibodies.” “We will actively introduce ICT technologies such as artificial intelligence and big data analysis of Hancom Group. He said that he will build a bridgehead that can grow into a comprehensive healthcare company by combining Hancom’s high brand recognition.